Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel B Keller-Evans

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
JCO Oncology Practice|June 18, 2026
Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid TumorsAdam H Fox, Rachel B Keller-Evans, Richard S P Huang, et al.
Cancer Research Communications|July 23, 2025
ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic ProfilingAllison W Kurian, Erica Gornstein, Lisa Heppler, et al.
The Oncologist|August 28, 2024
Breadth versus depth: whole transcriptome sequencing has reduced sensitivity for detection of clinically relevant fusions compared to RNA comprehensive genomic profilingRachel B Keller-Evans, Daniela Munafo, Tristen Ross, et al.
The Journal of Liquid Biopsy|March 3, 2025
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use casesAakash Desai, Lincoln W Pasquina, Candice Nulsen, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
The Oncologist|June 23, 2025
Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancerGerald Li, Stephanie B Greene, Baljinder Kaur, et al.
The Oncologist|January 9, 2026
DNA And RNA-Based Next-Generation Sequencing For Companion Diagnostic Rearrangement Detection In Solid TumorsRachel B Keller-Evans, Jessica K Lee, Justin M Allen, et al.
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
NPJ Precision Oncology|June 17, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fractionSaumya D Sisoudiya, Hanna Tukachinsky, Rachel B Keller-Evans, et al.
The Journal of Molecular Diagnostics : JMD|January 4, 2026
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapyRachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
JCO Oncology Practice|June 18, 2026
Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid TumorsAdam H Fox, Rachel B Keller-Evans, Richard S P Huang, et al.
Cancer Research Communications|July 23, 2025
ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic ProfilingAllison W Kurian, Erica Gornstein, Lisa Heppler, et al.
The Oncologist|August 28, 2024
Breadth versus depth: whole transcriptome sequencing has reduced sensitivity for detection of clinically relevant fusions compared to RNA comprehensive genomic profilingRachel B Keller-Evans, Daniela Munafo, Tristen Ross, et al.
The Journal of Liquid Biopsy|March 3, 2025
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use casesAakash Desai, Lincoln W Pasquina, Candice Nulsen, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
The Oncologist|June 23, 2025
Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancerGerald Li, Stephanie B Greene, Baljinder Kaur, et al.
The Oncologist|January 9, 2026
DNA And RNA-Based Next-Generation Sequencing For Companion Diagnostic Rearrangement Detection In Solid TumorsRachel B Keller-Evans, Jessica K Lee, Justin M Allen, et al.
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
NPJ Precision Oncology|June 17, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fractionSaumya D Sisoudiya, Hanna Tukachinsky, Rachel B Keller-Evans, et al.
The Journal of Molecular Diagnostics : JMD|January 4, 2026
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapyRachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, et al.
Pageof 1